Transplantation and Cellular Therapy Meetings | Conference

Dr. Walters on the Safety Profile of Beti-Cel in Pediatric Transfusion-Dependent Beta-Thalassemia

February 26th 2021

Mark Walters, MD, discusses the safety profile of betibeglogene autotemcel gene therapy in pediatric patients with transfusion-dependent β-thalassemia, as reported in the phase 3 Northstar-2 and Northstar-3 trials.

Dr. Cortes on Future Research Directions With CPX-351 in AML

February 26th 2021

Jorge E. Cortes, MD, discusses future directions in the research of CPX-351 in patients with acute myeloid leukemia.

Off-the-Shelf NK Immunotherapy With Chemotherapy and Transplant Shows Early Activity in B-Cell NHL

February 17th 2021

February 17, 2021 — Cord blood–derived natural killer immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant, showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma.

Itolizumab Leads to Sustained Clinical Responses in Newly Diagnosed Acute GVHD

February 16th 2021

February 16, 2021 - Itolizumab, a humanized IgG1 monoclonal antibody that modulates the activated leukocyte cell adhesion molecule pathway, represents a promising approach for the treatment of patients with newly diagnosed acute graft-versus-host disease.

Ruxolitinib Induces Improved Responses in Chronic GVHD

February 12th 2021

February 12, 2021 - Ruxolitinib demonstrated a significantly higher overall response rate compared with best available therapy among adolescent and adult patients with chronic graft-versus-host disease.

Dr. Solomon on the Effects of Liso-Cel in Prior Anti-CD19 Therapy–Treated B-NHL

February 11th 2021

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.

Dr. Nath on the Interim Results of the SIERRA Trial in Relapsed/Refractory AML

February 11th 2021

Rajneesh Nath, MD, discusses the interim results of the phase 3 SIERRA trial in patients with relapsed/refractory acute myeloid leukemia.

Orca-T Displays GVHD Prevention, Scalability Potential, and Tolerability in Hematologic Cancers

February 11th 2021

February 11, 2021 - Treatment with the first-generation precision cell therapy Orca-T led to a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, a lack of treatment-related mortalities, while showcasing scalability potential.

Iomab-B/Transplant Causes Fewer AEs Versus Conventional Care in AML

February 11th 2021

February 11, 2021 - A conditioning regimen comprised of targeted radiation with Iomab-B led to a lower incidence of sepsis as well as trends toward reduced rates of severe mucositis and febrile neutropenia versus conventional care and standard conditioning regimens in older adults with relapsed or refractory acute myeloid leukemia.

Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML

February 11th 2021

February 11, 2021 — Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia.

Omidubicel May Represent New Standard in Hematologic Cancers Eligible for Umbilical Cord Blood Transplantation

February 10th 2021

February 10, 2021 - Hematopoietic recovery following myeloablative transplantation with omidubicel was faster than standard myeloablative umbilical cord blood transplantation and was associated with encouraging clinical benefit.

Dr. Barata on Patient-Reported Toxicities With Axi-Cel at 1-Year of Follow-Up

February 10th 2021

Anna Barata, PhD, discusses patient-reported toxicities with axicabtagene ciloleucel (axi-cel) in patients 1-year post-infusion.

Dr. Wang on the Potential Utility of Ruxolitinib in Pediatric Patients With cGVHD

February 10th 2021

YunZu Michele Wang, MD, discusses the potential utility of ruxolitinib in children and young adult patients with chronic graft-versus-host disease.

Beti-Cel Results in Impressive Activity in Pediatric Transfusion-Dependent Beta-Thalassemia

February 10th 2021

February 10, 2021 - Treatment with the investigative gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients less than 18 years of age with transfusion-dependent beta-thalassemia with a median average hemoglobin of 11.3 g/dL.

CPX-351 Continues to Improve OS in High-Risk AML Subtypes

February 10th 2021

February 10, 2021 - CPX-351 demonstrated improved overall survival at 5 years versus standard 7+3 chemotherapy in older patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

Ruxolitinib Delivered at Maximum Dose Peri-Transplant Proves Safe in Myelofibrosis

February 10th 2021

February 10, 2021 - The JAK 1/2 inhibitor ruxolitinib, when given at a maximum dose of 10 mg peri-transplant, has been shown to be safe and feasible in patients with myelofibrosis.

Axi-Cel Active in Relapsed/Refractory B-Cell Lymphomas Irrespective of Chemo Sensitivity

February 9th 2021

February 9, 2021 - Responsiveness to treatment received immediately prior to CAR T-cell therapy may not be associated with post–CAR T outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma who receive axicabtagene ciloleucel.

Dr. Ahmed on Axi-Cel Benefit in Patients With Primary Refractory LBCL

February 9th 2021

Sairah Ahmed, MD, discusses the efficacy of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory large B-cell lymphoma (LBCL) who achieved complete remission (CR) to any prior treatment versus those who were primary refractory.

Dr. Horwitz on the Clinical Benefit of Omidubicel Transplant in Hematologic Malignancies

February 9th 2021

Mitchell E. Horwitz, MD, discusses the use of omidubicel versus standard myeloablative umbilical cord blood transplant in patients with hematologic malignancies.

Response to Prior Therapy Predicts Outcomes With Axi-Cel in Refractory Large B-Cell Lymphoma

February 9th 2021

February 9, 2021 - Patients with refractory large B-cell lymphoma have less to gain from axicabtagene ciloleucel if they have never achieved a complete response to any line of prior therapy.